- Joined
- Jul 10, 2008
- Messages
- 64,915
- Points
- 113
https://pubmed.ncbi.nlm.nih.gov/1690918/
The RW Malone referenced in the above article is not the same Robert Malone?
-
IP addresses are NOT logged in this forum so there's no point asking. Please note that this forum is full of homophobes, racists, lunatics, schizophrenics & absolute nut jobs with a smattering of geniuses, Chinese chauvinists, Moderate Muslims and last but not least a couple of "know-it-alls" constantly sprouting their dubious wisdom. If you believe that content generated by unsavory characters might cause you offense PLEASE LEAVE NOW! Sammyboy Admin and Staff are not responsible for your hurt feelings should you choose to read any of the content here. The OTHER forum is HERE so please stop asking.
[Video] - Dr. Robert Malone, inventor of mRNA vaccine technology, warns against taking the vaccine
- Thread starter UltimaOnline
- Start date
https://pubmed.ncbi.nlm.nih.gov/1690918/
The RW Malone referenced in the above article is not the same Robert Malone?
- Joined
- Sep 28, 2011
- Messages
- 4,133
- Points
- 113
Just talking about something doesn't make you an inventor of it. Go find out more about him.https://pubmed.ncbi.nlm.nih.gov/1690918/
The RW Malone referenced in the above article is not the same Robert Malone?
View attachment 116856
- Joined
- Jul 10, 2008
- Messages
- 64,915
- Points
- 113
I would agree with you if all he was doing was "talking" about something that was not his field of expertise. However according to the website he has submitted various papers and done a ton of research in the field of gene technology so it's not as if he's a charlatan who does not have a clue.
Are the various papers he submitted all fraudulent? If they are shouldn't they be flagged or removed?
https://pubmed.ncbi.nlm.nih.gov/?term=Malone+RW&cauthor_id=1690918
- Joined
- Aug 10, 2008
- Messages
- 106,000
- Points
- 113
She mentioned 'Singapore'. Worth viewing the entire thing.
https://www.bitchute.com/video/u5wzMW0wAulm/
- Joined
- Jul 10, 2008
- Messages
- 64,915
- Points
- 113
Here's a recent article. It seems that RW Malone is actively involved in finding anti viral agents that work against Covid-19 which, if successful, no longer necessitate mass vaccination provided the anti viral approach reduces the severity and mortality of COVID-19 to the point where it is no worse than existing Coronaviruses or milder flu strains.
If this is the case then I can well understand why the drug companies are trying to discredit and cancel him as it would severely affect their profitability.
https://trialsitenews.com/rw-malone...alth-testing-famotidine-in-covid-19-patients/
TrialSite Staff April 27, 2020
W. Malone MD, LLC announced the enrollment of an innovative, rigorous clinical trial designed to rapidly assess the safety and clinical benefit of a combination of two widely available and inexpensive repurposed generic drugs for treatment of hospitalized patients suffering with COVID-19. Under the guidance of Dr. Malone, clinical trials were initiated at Northwell Health system in New York. Malone was a key participant in a multi-faceted collaboration involving physicians and scientists from multiple institutions. This clinical trial provides patients hospitalized with COVID-19 disease the opportunity to volunteer for a clinical trial that may bring new hope to all at risk for infection by the SARS-CoV-2 virus. Malone is reported to be part of efforts to employ computer simulations, Artificial Intelligence and other methods are used to study which drugs could be repurposed to counter threats such as COVID-19, also collaborated extensively with The Office of the Assistant Secretary for Preparedness and Response (HHS) and the Department of Defense; Defense Threat Reduction Agency.
The Study
The clinical trial is being conducted at New York State’s largest health care provider and private employer, with 23 hospitals and nearly 800 outpatient facilities, Northwell Health is continually striving to find more innovative and effective ways to improve the health of our patients, our communities, our country, and the world.
About Drug Repurposing for Infectious Disease Outbreaks
When confronting a rapidly moving epidemic or global pandemic caused by a new and highly infectious respiratory virus, time is of the essence, and every day can be measured by thousands more people infected, suffering or dying. The pressing need to rapidly develop drug or vaccine treatments or preventions can be overwhelming. However, those with experience in managing outbreaks are aware of the risks of rushing an unproven drug or vaccine into widespread use before demonstrating both effectiveness and safety; many millions of people could be further damaged if dosed or vaccinated with unsafe medical products. Unfortunately, demonstrating both the safety and the ability to reduce or prevent viral disease for a new drug or vaccine for a new virus takes large amounts of time, money, and risk; usually 10 to 15 or more years, billions of dollars for each candidate, and often ends in failure. The Merck Ebola vaccine was moved through the process from initial human testing to FDA licensure in a record time of five years.
One option for accelerating this process is to focus on identifying drugs that have already been licensed by the FDA for treating other diseases; repurposing them for a new “off label” use. This strategy can save valuable time because the safety, manufacturing processes, and pharmaceutical characteristics of a repurposed antiviral drug candidate has already been demonstrated and reviewed by the FDA. The remaining challenge is to rapidly determine which of the thousands of licensed drugs might be useful for preventing or treating the viral disease, to rigorously test the safety and efficacy of a candidate treatment in properly controlled clinical trials, and to do this as fast as possible. Days lost translate into lives lost.
There are three general approaches for discovering whether the library of old drugs can be useful for treating new viral diseases. One is to test each drug one by one for ability to halt the replication of the virus. This approach is relatively slow and can now be speeded up by using advanced robotics technologies (high throughput screening), but even if a drug blocks a virus from replicating in cells it may not work in animals or humans to stop the disease. This method typically requires time consuming animal testing. Another recently developed method uses advanced high-performance computing to analyze the three-dimensional structure of virus proteins and predict whether a drug may block the ability of a virus to replicate. By using supercomputers or cloud-based computing, this method can select likely drug candidates from the library of all licensed drugs in just hours. A third approach also involves modern computer technology, but sorts through large clinical data sets to identify medical conditions and drug treatments that seem to protect some people from disease relative to others who are not taking the drug (“survival signals”). All three of these approaches are being used by physicians and scientists all over the world in an open cooperative effort aimed at combatting the COVID-19 pandemic.
Discovery of Famotidine as a Possible Repurposed Drug Treatment for COVID-19 Disease
Famotidine is sold as an over the counter, generic, inexpensive oral pill that is commonly used for relief of heartburn, acid indigestion, and sour stomach. In prescription form (oral or IV), famotidine is used for treatment of duodenal ulcer; gastroesophageal reflux disease (GERD), active benign gastric ulcer and certain other conditions involving excess stomach acid. Famotidine is inexpensive, remarkably safe, easily manufactured, rapidly absorbed into the blood and readily distributed throughout the body. Further information including safety information about famotidine can be found here.
Dr. Robert Malone is an internationally recognized physician scientist (virology, immunology, molecular biology, and drug discovery) and is known as one of the original inventors of DNA and RNA Vaccination. Together with his partner, also a scientist, Dr. Malone co-founded and is president of RW Malone MD, LLC, where he serves as principal consultant. When the sequence of the novel coronavirus (now known as SARS-CoV-2) was publicly disclosed on January 10, Dr. Malone and his colleagues began volunteering their time to find an antiviral treatment, knowing that a successful vaccine licensure would be years away. They began applying advanced supercomputing tools to determine whether any FDA licensed drugs or other nutraceuticals might be used to treat COVID-19 disease. This work by the team has been entirely voluntary, performed as “open source” research aimed at finding a potential repurposed drug treatment for COVID-19 while also demonstrating the usefulness of the system developed in support of DTRA rapid medical countermeasure development objectives. The team chose to focus on a SARS-CoV-2 virus protein that has been overlooked by many large pharmaceutical companies; a protein involved in early stages of virus replication, which also suppresses parts of the immune response to SARS-CoV-2 and other viruses. Of the top ranked drugs identified by applying the drug discovery system developed for DTRA, the team determined that famotidine had the most attractive combination of safety, cost, and pharmaceutical characteristics. The success of the system to identify and rapidly advance a repurposed drug candidate for treatment of COVID-19 disease has demonstrated the usefulness of the DTRA approach. Dr. Malone presented a summary of the findings and recommendations to Dr. Callahan and the ASPR. The mission of the HHS Office of the Assistant Secretary for Preparedness and Response (ASPR) is to save lives and protect Americans from 21st century health security threats
Original Observations out of China
Dr. Michael Callahan is a physician scientist that works as an infectious disease, mass casualty infection doctor at the Massachusetts General Hospital in Boston, MA, and who has developed block-buster anti-infective drugs for the U.S. Government and for Industry, has a joint clinical appointment at a sister hospital in China. Dr. Callahan also serves as a senior executive at United Therapeutics, a publicly traded company that is focused on pulmonary hypertension and oncology. Dr. Callahan is triple boarded in internal medicine, infectious disease, tropical medicine, and is one of the few Command physicians based in the United States who specialize in mass casualty infection therapies. Over the last 17 years, Dr. Callahan has managed treatment of over 1000 Ebola patients across five outbreaks in three countries and previously deployed to 3 bird flu outbreaks and the 2002-03 SARS outbreak in Hong Kong.
With the advent of the outbreak of a novel coronavirus infection during December 2019, Dr. Callahan was granted a leave of absence by United Therapeutics’ CEO Martine Rothblatt to travel to China to assist clinical colleagues in mass infection management of COVID 19 under his joint appointment. Unaware of the work by Dr. Malone, Dr. Callahan worked with Asian colleagues to analyze medical records from over 6,000 hospitalized patients, 1,100 of whom had severe disease. This analysis of clinical data revealed that about 600 of these patients were on antacid therapies, and were found to have relatively mild COVID-19 disease compared to others of similar age and health. The incidence of COVID-19 in China dropped quickly, and Dr. Callahan and colleagues were not able to start a clinical trial to test famotidine as a promising oral therapy for treating COVID-19 disease. Dr. Callahan was then recruited to serve as Special Advisor on COVID 19 to the Assistant Secretary of Public Health Preparedness and Response (ASPR), U.S Dept of Health and Human Services during this pandemic, and his leave of absence from United Therapeutics was extended due to the pressing emergency. Since appointment, has been working within the office of the Assistant Secretary to assist policy and management decisions while also lending his experience on the front lines in intensive care units across the country.
Dr. Malone presented a summary of the team findings and recommendations to the ASPR on 18 March 2020. Both Dr. Callahan and Dr. Malone were previously unaware of each other’s work and agreed to collaborate on this project. As old friends, it is not the first time that they have worked to “save the world”. With convergence of these two independent discoveries, Feinstein/Northwell Health system was contacted to explore the possibility of performing well controlled clinical trials within the Northwell hospital system. Northwell hospital system agreed that this repurposed drug candidate worthy of rigorous evaluation of activity in randomized clinical trials. Because New York decided that the standard of care for hospitalized COVID-19 patients was to include hydroxychloroquine, this was added to the study arms to ensure enrollment of patients and comply with bioethical requirements for inclusion of standard of care in clinical trial designs.
Dr. Malone then wrote the initial clinical protocol. This was reviewed and edited by Dr. Robert Malone together with Drs. Martin Lesser, a biostatician, and Joe Conigliary, a general internal medicine doctor within the Northwell hospital system. Robert was also the primary technical author writing the federal funding contract, which was subsequently funded by BARDA for over 20 million dollars, three days later, to perform this clinical trial. Under this contract, Alchem Laboratories is prime contractor and Northwell health system became a sub-contractor for the BARDA award for advancement of this drug.
The volunteer team includes Dr. Joshua Patel of Molecular Forecasting, Dr. Gideon Shapiro, and Dr. Jill Glasspool Malone. We are grateful for this team and what they have accomplished.
About RW Malone MD, LLC
RW Malone MD, LLC offers premier consulting, analytics and proposal development services that specialize in a unique blend of detail-oriented, efficient and value-oriented processes. This enables the synergy required to move projects and product development teams forward by complementing and supporting core client expertise. Core competencies include pre and clinical trials expertise, clinical trial design and implementation, vaccine and biologics, AI drug development, outbreak disease expertise, expert witness due diligence and proposal development.
If this is the case then I can well understand why the drug companies are trying to discredit and cancel him as it would severely affect their profitability.
https://trialsitenews.com/rw-malone...alth-testing-famotidine-in-covid-19-patients/
RW. Malone Contributes to Potential Breakthrough Clinical Trial at Northwell Health Testing Famotidine in COVID-19 Patients
TrialSite Staff April 27, 2020
W. Malone MD, LLC announced the enrollment of an innovative, rigorous clinical trial designed to rapidly assess the safety and clinical benefit of a combination of two widely available and inexpensive repurposed generic drugs for treatment of hospitalized patients suffering with COVID-19. Under the guidance of Dr. Malone, clinical trials were initiated at Northwell Health system in New York. Malone was a key participant in a multi-faceted collaboration involving physicians and scientists from multiple institutions. This clinical trial provides patients hospitalized with COVID-19 disease the opportunity to volunteer for a clinical trial that may bring new hope to all at risk for infection by the SARS-CoV-2 virus. Malone is reported to be part of efforts to employ computer simulations, Artificial Intelligence and other methods are used to study which drugs could be repurposed to counter threats such as COVID-19, also collaborated extensively with The Office of the Assistant Secretary for Preparedness and Response (HHS) and the Department of Defense; Defense Threat Reduction Agency.
The Study
The clinical trial is being conducted at New York State’s largest health care provider and private employer, with 23 hospitals and nearly 800 outpatient facilities, Northwell Health is continually striving to find more innovative and effective ways to improve the health of our patients, our communities, our country, and the world.
About Drug Repurposing for Infectious Disease Outbreaks
When confronting a rapidly moving epidemic or global pandemic caused by a new and highly infectious respiratory virus, time is of the essence, and every day can be measured by thousands more people infected, suffering or dying. The pressing need to rapidly develop drug or vaccine treatments or preventions can be overwhelming. However, those with experience in managing outbreaks are aware of the risks of rushing an unproven drug or vaccine into widespread use before demonstrating both effectiveness and safety; many millions of people could be further damaged if dosed or vaccinated with unsafe medical products. Unfortunately, demonstrating both the safety and the ability to reduce or prevent viral disease for a new drug or vaccine for a new virus takes large amounts of time, money, and risk; usually 10 to 15 or more years, billions of dollars for each candidate, and often ends in failure. The Merck Ebola vaccine was moved through the process from initial human testing to FDA licensure in a record time of five years.
One option for accelerating this process is to focus on identifying drugs that have already been licensed by the FDA for treating other diseases; repurposing them for a new “off label” use. This strategy can save valuable time because the safety, manufacturing processes, and pharmaceutical characteristics of a repurposed antiviral drug candidate has already been demonstrated and reviewed by the FDA. The remaining challenge is to rapidly determine which of the thousands of licensed drugs might be useful for preventing or treating the viral disease, to rigorously test the safety and efficacy of a candidate treatment in properly controlled clinical trials, and to do this as fast as possible. Days lost translate into lives lost.
There are three general approaches for discovering whether the library of old drugs can be useful for treating new viral diseases. One is to test each drug one by one for ability to halt the replication of the virus. This approach is relatively slow and can now be speeded up by using advanced robotics technologies (high throughput screening), but even if a drug blocks a virus from replicating in cells it may not work in animals or humans to stop the disease. This method typically requires time consuming animal testing. Another recently developed method uses advanced high-performance computing to analyze the three-dimensional structure of virus proteins and predict whether a drug may block the ability of a virus to replicate. By using supercomputers or cloud-based computing, this method can select likely drug candidates from the library of all licensed drugs in just hours. A third approach also involves modern computer technology, but sorts through large clinical data sets to identify medical conditions and drug treatments that seem to protect some people from disease relative to others who are not taking the drug (“survival signals”). All three of these approaches are being used by physicians and scientists all over the world in an open cooperative effort aimed at combatting the COVID-19 pandemic.
Discovery of Famotidine as a Possible Repurposed Drug Treatment for COVID-19 Disease
Famotidine is sold as an over the counter, generic, inexpensive oral pill that is commonly used for relief of heartburn, acid indigestion, and sour stomach. In prescription form (oral or IV), famotidine is used for treatment of duodenal ulcer; gastroesophageal reflux disease (GERD), active benign gastric ulcer and certain other conditions involving excess stomach acid. Famotidine is inexpensive, remarkably safe, easily manufactured, rapidly absorbed into the blood and readily distributed throughout the body. Further information including safety information about famotidine can be found here.
Dr. Robert Malone is an internationally recognized physician scientist (virology, immunology, molecular biology, and drug discovery) and is known as one of the original inventors of DNA and RNA Vaccination. Together with his partner, also a scientist, Dr. Malone co-founded and is president of RW Malone MD, LLC, where he serves as principal consultant. When the sequence of the novel coronavirus (now known as SARS-CoV-2) was publicly disclosed on January 10, Dr. Malone and his colleagues began volunteering their time to find an antiviral treatment, knowing that a successful vaccine licensure would be years away. They began applying advanced supercomputing tools to determine whether any FDA licensed drugs or other nutraceuticals might be used to treat COVID-19 disease. This work by the team has been entirely voluntary, performed as “open source” research aimed at finding a potential repurposed drug treatment for COVID-19 while also demonstrating the usefulness of the system developed in support of DTRA rapid medical countermeasure development objectives. The team chose to focus on a SARS-CoV-2 virus protein that has been overlooked by many large pharmaceutical companies; a protein involved in early stages of virus replication, which also suppresses parts of the immune response to SARS-CoV-2 and other viruses. Of the top ranked drugs identified by applying the drug discovery system developed for DTRA, the team determined that famotidine had the most attractive combination of safety, cost, and pharmaceutical characteristics. The success of the system to identify and rapidly advance a repurposed drug candidate for treatment of COVID-19 disease has demonstrated the usefulness of the DTRA approach. Dr. Malone presented a summary of the findings and recommendations to Dr. Callahan and the ASPR. The mission of the HHS Office of the Assistant Secretary for Preparedness and Response (ASPR) is to save lives and protect Americans from 21st century health security threats
Original Observations out of China
Dr. Michael Callahan is a physician scientist that works as an infectious disease, mass casualty infection doctor at the Massachusetts General Hospital in Boston, MA, and who has developed block-buster anti-infective drugs for the U.S. Government and for Industry, has a joint clinical appointment at a sister hospital in China. Dr. Callahan also serves as a senior executive at United Therapeutics, a publicly traded company that is focused on pulmonary hypertension and oncology. Dr. Callahan is triple boarded in internal medicine, infectious disease, tropical medicine, and is one of the few Command physicians based in the United States who specialize in mass casualty infection therapies. Over the last 17 years, Dr. Callahan has managed treatment of over 1000 Ebola patients across five outbreaks in three countries and previously deployed to 3 bird flu outbreaks and the 2002-03 SARS outbreak in Hong Kong.
With the advent of the outbreak of a novel coronavirus infection during December 2019, Dr. Callahan was granted a leave of absence by United Therapeutics’ CEO Martine Rothblatt to travel to China to assist clinical colleagues in mass infection management of COVID 19 under his joint appointment. Unaware of the work by Dr. Malone, Dr. Callahan worked with Asian colleagues to analyze medical records from over 6,000 hospitalized patients, 1,100 of whom had severe disease. This analysis of clinical data revealed that about 600 of these patients were on antacid therapies, and were found to have relatively mild COVID-19 disease compared to others of similar age and health. The incidence of COVID-19 in China dropped quickly, and Dr. Callahan and colleagues were not able to start a clinical trial to test famotidine as a promising oral therapy for treating COVID-19 disease. Dr. Callahan was then recruited to serve as Special Advisor on COVID 19 to the Assistant Secretary of Public Health Preparedness and Response (ASPR), U.S Dept of Health and Human Services during this pandemic, and his leave of absence from United Therapeutics was extended due to the pressing emergency. Since appointment, has been working within the office of the Assistant Secretary to assist policy and management decisions while also lending his experience on the front lines in intensive care units across the country.
Dr. Malone presented a summary of the team findings and recommendations to the ASPR on 18 March 2020. Both Dr. Callahan and Dr. Malone were previously unaware of each other’s work and agreed to collaborate on this project. As old friends, it is not the first time that they have worked to “save the world”. With convergence of these two independent discoveries, Feinstein/Northwell Health system was contacted to explore the possibility of performing well controlled clinical trials within the Northwell hospital system. Northwell hospital system agreed that this repurposed drug candidate worthy of rigorous evaluation of activity in randomized clinical trials. Because New York decided that the standard of care for hospitalized COVID-19 patients was to include hydroxychloroquine, this was added to the study arms to ensure enrollment of patients and comply with bioethical requirements for inclusion of standard of care in clinical trial designs.
Dr. Malone then wrote the initial clinical protocol. This was reviewed and edited by Dr. Robert Malone together with Drs. Martin Lesser, a biostatician, and Joe Conigliary, a general internal medicine doctor within the Northwell hospital system. Robert was also the primary technical author writing the federal funding contract, which was subsequently funded by BARDA for over 20 million dollars, three days later, to perform this clinical trial. Under this contract, Alchem Laboratories is prime contractor and Northwell health system became a sub-contractor for the BARDA award for advancement of this drug.
The volunteer team includes Dr. Joshua Patel of Molecular Forecasting, Dr. Gideon Shapiro, and Dr. Jill Glasspool Malone. We are grateful for this team and what they have accomplished.
About RW Malone MD, LLC
RW Malone MD, LLC offers premier consulting, analytics and proposal development services that specialize in a unique blend of detail-oriented, efficient and value-oriented processes. This enables the synergy required to move projects and product development teams forward by complementing and supporting core client expertise. Core competencies include pre and clinical trials expertise, clinical trial design and implementation, vaccine and biologics, AI drug development, outbreak disease expertise, expert witness due diligence and proposal development.
She mentioned 'Singapore'. Worth viewing the entire thing.
https://www.bitchute.com/video/u5wzMW0wAulm/
Winter time will be a big test if Ade will Kenna alot of vaccinated ppl
- Joined
- Jul 10, 2008
- Messages
- 64,915
- Points
- 113
It does not make sense for any drug company or government to knowingly administer a vaccine that is going to wipe out half the population or more. Businesses need customers and governments need serfs to lord over.
My view remains the same. The vaccines could be God's gift to mankind and mRNA technology could transform lives, conquer cancer and fix genes responsible for many genetic diseases that can result in a horrible death. However the short cuts taken in the "approval" process means that their safety and longer term efficacy is still a big unknown.
- Joined
- Jul 16, 2008
- Messages
- 24,585
- Points
- 113
He never said that. He has an MD, he wouldn't make such a basic error. Watch the video (instead of some other source putting words into his mouth) :
Therein lies the problem. The assumption is the spike proteins assembled in the body are harmless, but Dr. Robert Malone is saying they are actually biologically active and cause an entire variety of medical problems (see list below). He said he warned FDA about this, but FDA (under political pressure to save USA from the Covid pandemic) replied him that to date there's "insufficient evidence" for the biological activity of the assembled spike proteins. Absence of proof is not proof of absence.
https://www.gov.uk/government/publications/coronavirus-covid-19-vaccine-adverse-reactions
Last edited:
I hope the vaccine is really very bad and causes lots of death and paralysis.
Basiclaly more than half the world dies. Good lah. Less poverty. No more global warming. Restatt.
The ones left behind will either be happier or cursed in a more chaotic world filled with anti vaxxers and rebels.
I would prefer to be dead. Please pleade let it be true.
Basiclaly more than half the world dies. Good lah. Less poverty. No more global warming. Restatt.
The ones left behind will either be happier or cursed in a more chaotic world filled with anti vaxxers and rebels.
I would prefer to be dead. Please pleade let it be true.
- Joined
- Sep 28, 2011
- Messages
- 4,133
- Points
- 113
- Joined
- Jul 10, 2008
- Messages
- 64,915
- Points
- 113
Hardly a "fact check" simply because many of the points are about interpreting grey areas.
Take this for example :
To label this as "false" is ridiculous. Some are of the opinion that the risk to children is so low that vaccinations don't make sense and could be more risky than Covid. Some believe that children should be vaccinated so that they don't transmit the virus to the more vulnerable. There is no right/wrong answer. It's simply two opposing opinions. The only way of knowing which approach is better is to conduct a large, truly randomised trial that compared the two approaches to decide which gives a better outcome and we all know this won't happen as there are simply too many variables to make an accurate comparison.
- Joined
- Jul 25, 2008
- Messages
- 60,398
- Points
- 113
this is what he said (in bold and last in double quotations with source provided below).
‘On June 10, 2021, Dr. Malone joined biologist Bret Weinstein, Ph.D, on the Dark Horse Podcast, where Malone raised numerous safety concerns about the Pfizer-BioNTech and Moderna COVID-19 vaccines, both of which use mRNA technology. He warned about future autoimmune issues caused by the spike proteins within the mRNA injections.
Malone also stated that the Food and Drug Administration (FDA) was aware that the spike proteins were “biologically active and could travel from the injection site and cause adverse events, and that the spike protein, if biologically active, is very dangerous.”’
https://www.lifesitenews.com/news/i...dia-after-he-warned-against-taking-covid-jabs
"spike proteins within the mrna injections"; spike proteins "could travel from the injection site" - he's alluding to spike proteins being injected with the mrna injections and traveling into the body. for the immune response to work at over 90% efficacy, the spike protein has to be active to cause a more robust immune response. this is why vaccines relying on deactivated viruses pale in comparison to mrna vaccines in terms of efficacy and effectiveness. i'd rather have active (non-viral) spike proteins continue to exist in my body to keep the immune system on its toes than have dead viruses or inactivated ones swimming around.
Last edited:
- Joined
- Jul 10, 2008
- Messages
- 64,915
- Points
- 113
Here's one of the "fact checkers" from logically.ai.
Just how someone with a degree from an Indian Uni who has zero medical qualifications can fact check a senior medical researcher and qualified doctor is beyond me.
To be honest I would hold the opinion of @eatshitndie in far higher regard based upon his track record in this forum.
Who is checking the fact checkers?
U guys go see a video. Basically one does of moderna jab got 4 trillions RNA injected in. Then will go to ur cells tell ur cells produce spike proteins. The vaccine is supposed to stay in the muscle area but 75% of it will end up in the blood vessels. Then the spike protein will attached to the micro blood vessels wall. Then when blood passes through, they thought those spikes attached to the blood vessels wall are damage vessels. The will cloy there to repair it. Thus causing tiredness and clots in ppl. The clots are micro can only be detected by d-dimer blood test.
Similar threads
